Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society

This consensus reviewed the main current issues of clinical application and integration into everyday practice a new targeted preventive therapy for migraine using monoclonal antibodies (mAbs) to calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on scientific studies an analysis results several years use. The purpose is assist practitioners in prescribing effective prophylactic treatment anti-CGRP mAbs improve care patients with various forms disease.